Investigators found that antiangiogenic treatment facilitated non–small cell lung cancer tumor infiltration by PD-1+ regulatory T cells, which were more efficiently targeted by the PD-1 antibody than CD8+ T cells.
[Science Translational Medicine]
Sorry, but the selected Zotpress account can't be found.